21Shares has filed an amended S-1/A registration statement with the U.S. Securities and Exchange Commission for its Injective ETF, according to Crypto Briefing. The filing updates the original application submitted in October 2025. If approved, the fund would trade on Nasdaq under the ticker TINJ and passively track the performance of the INJ token through the FTSE Injective Index. The filing also says the ETF may stake a portion of its holdings at its discretion to enhance yield. 21Shares has already launched an Injective staking ETP in Europe, and the new filing represents an expansion effort into the U.S. market.
21Shares has submitted an amended S-1/A registration statement to the U.S. Securities and Exchange Commission for its Injective ETF, according to Crypto Briefing. The updated filing revises the original application submitted in October 2025.
If approved, the ETF would list on Nasdaq under the ticker TINJ and passively track the performance of the INJ token through the FTSE Injective Index.
The filing says the fund may also stake part of its holdings at its discretion to enhance yield.
21Shares previously launched an Injective staking ETP in Europe. This filing extends that product push into the U.S. market.
This article was originally published by Bit.Fan. For more cryptocurrency news and market insights, visit www.bit.fan. Disclaimer:
The market information, project data, and third-party content displayed on this platform are for industry information sharing only and do not constitute any form of investment advice or return commitment.
Cryptocurrency trading carries high risks. Users should fully assess their risk tolerance and make independent decisions. All profits, losses, and legal responsibilities are borne by the users themselves.
